Associate Editor


Nabanita Mukherjee, PhD

Post-Doctoral Researcher
Department of Dermatology
Anschutz Medical Campus
University of Colorado
1201 Larimer St. Denver, CO 80204, USA

Biography

Dr. Mukherjee currently working as a Post-Doctoral Researcher in the Department of Dermatology at University of Colorado Denver. The aim of her current research project is to understand the mechanisms involved in melanoma chemoresistance and to develop methods to reverse the resistance of melanoma to therapy. She serve as a reviewer in multiple cancer journals. She obtained her PhD degree in Neuroscience from University of Vermont under the guidance of Dr. Eugene R. Delay. Her dissertation project was designed to look at the effects of chemotherapy drugs on the afferent taste signaling pathway. Previously, she obtained her Bachelors and Masters degree from University of Calcutta, India.

Research Interest

Her research interests include Dermatology, Melanoma and Cancer stem cells.

Scientific Activities

AWARDS AND HONORS


• (2015) Post-Doctoral Travel Award
• (2012) Graduate Research Fellowship, University of Vermont
• (2011) Graduate Student Assistantship, NSF
• (2011) Ronald Suiter Award, University of Vermont
• (2011) Travel Mini Grant Spring 2010 and Fall 2011
• (2009-2010) Vermont Genetics Network Graduate Research Assistantship, 2009-2010, sponsored by NIH, USA
• (2010) Travel Mini Grant
• (2007) Abroad Travel Award, University of Calcutta
• (2006) Meritorious student medal as undergraduate student

Publications

1. Mukherjee N, Josianna V, Schwan, Fujita M, Shellman YJ, Norris DA. New alternative treatments for melanoma.targeting BCL-2 family members to de-bulk and kill cancer stem cells. J Invest Dermatol. 2015; 135: 2155-2161 doi: 10.1038/jid.2015.145
2. Mukherjee N, Reuland SN, Lu Y, et al. Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells. J Invest Dermatol. 2015; 135: 842-850. doi: 10.1038/jid.2014.464
3. Mukherjee N, Carroll BL, Spees JL, Delay ER Pre-treatment with Amifostine protects against Cyclophosphamide-induced disruption of taste in mice. PLoS ONE. 2013; 8(4): e61607. doi: 10.1371/annotation/5487e265-8175-47cb-b9a4-d85862a4a96f
4. Mukherjee N, Delay ER. Cyclophosphamide - induced disruption of umami taste functions and taste epithelium. Neuroscience. 2011; 192: 732-745. doi: 10.1016/j.neuroscience.2011.07.006